Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation
Background and objectives: A new pandemic has emerged across the world:Covid-19. Covid-19 has affected hundreds of millions of people globally. To stop the spread of the virus and gain a mass immunity several vaccines have been developed. BNT162b2-mRNA-vaccine has been shown to be largely effective...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
PAGEPress Publications
2022-02-01
|
| Cyfres: | Mediterranean Journal of Hematology and Infectious Diseases |
| Pynciau: | |
| Mynediad Ar-lein: | http://mjhid.org/index.php/mjhid/article/view/4820 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|